Patrick Salmon

After qualifying as a physician Patrick Salmon spent several years in clinical medicine later entering the area of clinical research.

While working for Contract Research Organisation in Ireland and the UK, Patrick organised and ran phase 1, 2, and 3 studies. After a short period working with a pharmaceutical company, he joined the Irish regulatory agency in 1994 and has worked there since, assessing medical aspects of all types of applications.

His areas of involvement include clinical trial assessment; mutual recognition and decentralised applications; and centralised applications.

In 2000, Patrick became a member of the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). Later in 2004, he became an Irish delegate on the Committee for Orphan Medicinal Products (COMP) also at the EMA.

Additional interests include Product Information and he is Chair of the CHMP ad hoc group on the SmPC (Summary of Product Characteristics) and the CMD(h) (Co-ordination group for Mutual Recognition and Decentralised Procedures (human)) subgroup on harmonisation of the SmPC.

The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseasesRare Disease International Bringing together patients, families and experts to share experiences in a moderated multi-language forum. RareConnect The Rare Barometer Programme is a EURORDIS initiative that carries out surveys to transform rare disease patients' experiences into figures and facts that can be shared with decision-makers.Rare Barometer An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases